Search
Pamicogrel
go.drugbank.com/drugs/DB19812ExperimentalPamicogrel is a small molecule drug. Pamicogrel has a monoisotopic molecular weight of 448.15 Da.
Categories: Heterocyclic Compounds, 1-RingNobiprostolan
go.drugbank.com/drugs/DB19814ExperimentalNobiprostolan is a small molecule drug. Nobiprostolan has a monoisotopic molecular weight of 468.35 Da.
MIP-1095 I-131
go.drugbank.com/drugs/DB14978InvestigationalMIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
Nomacopan
go.drugbank.com/drugs/DB14991InvestigationalNomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Categories: Recombinant Protein Inhibitor of Complement Factor 5Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … to a different glycosylation pattern.
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigationalCold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures. … [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore
Synonyms: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent sPateclizumab
go.drugbank.com/drugs/DB14997InvestigationalPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared … With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
Human interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalIt is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.
Categories: Interferon Type IDianexin
go.drugbank.com/drugs/DB15000InvestigationalDianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigational[L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker. … Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm<sup>3</sup>), is a potential side effect of myelosuppressive chemotherapy